Table 2.
Clinical characteristics of AC-treated and untreated BC patients.
| Characteristics | Categories | Untreated (n=100) | Treated (n=100) | P-value |
|---|---|---|---|---|
| WHO clinical stage, n (%) | Stage 1 | 26 (26) | 22 (22) | 0.705 |
| Stage 2 | 31 (31) | 34 (34) | ||
| Stage 3 | 21 (21) | 26 (26) | ||
| Stage 4 | 22 (22) | 18 (18) | ||
| Metastasis, n (%) | Yes | 22 (22) | 17 (18) | 0.372 |
| No | 78 (78) | 83 (82) | ||
| BMI, n (%) | <18 Kg/m2 | 5 (5) | 6 (6) | 0.793 |
| 18-24.5 Kg/m2 | 65 (65) | 70 (70) | ||
| 25-29.5 Kg/m2 | 15 (15) | 11 (11) | ||
| ≥30 Kg/m2 | 15 (15) | 13 (13) | ||
| BMI (Mean ± SD) | 25.13 ± 4.0 | 24.22 ± 3.7 | 0.100 | |
| BP (Mean ± SD) | SBP (mmHg) | 119.42 ± 1.87 | 118.9 ± 1.9 | 0.060 |
| DBP (mmHg) | 79.0 ± 2.13 | 78.6 ± 2.1 | 0.182 |
AC, Adriamycin-Cytoxan; BC, breast cancer; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; and SD, Standard Deviation. Categorical variables were also expressed as numbers (n) and percentages (%). Continuous variables were expressed as mean ± standard deviation (SD). P-value of < 0.05 implies a significant difference between groups.